Log In
BCIQ
Print this Print this
 

Revusiran (ALN-TTRsc, SAR438714)

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionSubcutaneous RNAi therapeutic targeting the transthyretin (TTR) gene using the GalNAc-conjugate delivery platform
Molecular Target Transthyretin (TTR)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase III
Standard IndicationAmyloidosis
Indication DetailsTreat familial amyloidotic cardiomyopathy (FAC); Treat transthyretin (TTR) cardiac amyloidosis; Treat transthyretin (TTR)-mediated amyloidosis
Regulatory Designation U.S. - Orphan Drug (Treat transthyretin (TTR)-mediated amyloidosis)
PartnerSanofi

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$72.5M

$22.5M

$50.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/29/2012

$72.5M

$22.5M

$50.0M

Get a free BioCentury trial today